LG
VRTX icon

LaFleur & Godfrey’s Vertex Pharmaceuticals VRTX Stock Holding History

LaFleur & Godfrey’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382K Buy
769
+25
+3% +$11.1K 0.05% 117
2026
Q1 		$332K Buy
744
+262
+54% +$122K 0.04% 117
2025
Q4 		$219K Buy
+482
New +$208K 0.03% 142

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

LaFleur & Godfrey's VRTX Position: Q2 2026 in Review

LaFleur & Godfrey increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q2 2026, buying an estimated $11.1K and bringing the position to 769 shares worth $382K. The position accounts for 0.05% of the portfolio, ranked #117.

LaFleur & Godfrey first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LaFleur & Godfrey held 769 shares of Vertex Pharmaceuticals worth $382K as of Q2 2026.
  • LaFleur & Godfrey bought 25 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.1K.
  • Vertex Pharmaceuticals made up 0.05% of LaFleur & Godfrey's portfolio in Q2 2026, its #117 holding.
  • LaFleur & Godfrey first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LaFleur & Godfrey's 13F filing for Q2 2026, filed 15 Jul 2026.